Fresh Frozen Facts Part 4: A Thoughtful Look at Plasma Transfusion by Dr. Caitlin Raymond
Caitlin Raymond, MD/PhD shared an insightful chain of posts on LinkedIn:
”Fresh Frozen Facts, Part IV: Beyond the Blood Bag
We’ve spent the last three posts unpacking the nuances of plasma as a transfusion product — thawed, typed, and delivered with varying degrees of clarity and clinical intent. But plasma’s story doesn’t stop there.
In Part IV, we explore what happens after donation — when plasma is fractionated, purified, and turned into targeted biologics that power modern hematology, neurology, rheumatology, immunology, and more.
From albumin for oncotic support to IVIG for immune modulation and Rh immune globulin for alloimmunization prevention, these plasma-derived therapies are more than just “blood products.” They’re precision tools — crafted for specific indications and held to pharmaceutical-grade standards.
We cover:
- Albumin: when it’s the right choice — and when it isn’t
- IVIG: how it works, when to use it, and key risks to know
- RhIg: an elegant triumph of targeted immunotherapy
- Hyperimmune globulins, antithrombin, C1 esterase inhibitor, and more
- The evolving landscape of patient-centered transfusion, including care for Jehovah’s Witnesses and the legacy of hemophilia and HIV
This final installment is about precision, stewardship, and respect — for the science and the people behind every plasma product.
And if you’ve missed the earlier parts of the series, now’s the time to catch up.
Because transfusion medicine doesn’t end with a blood bag — and sometimes the most powerful plasma products don’t look like blood at all.
Read the full post here.
Caitlin Raymond, MD/PhD, has launched an educational series on Fresh Frozen Plasma (FFP), now available on her journal blog.
Enjoy the final part and make sure you do not miss all the Fresh Frozen Facts!
Stay tuned for updates to the Fresh Frozen Facts series on Hemostasis Today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits